AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20966444 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 134
Study 16106024 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 62000
Study 16106024 — intervention group
Group type: COMPARATOR
Intervention: Interval cancers
Number of subjects: 62000
Study 16106024 — intervention group
Group type: COMPARATOR
Intervention: Control groups (non-screened)
Number of subjects: 62000
Study 11891487 — intervention group
Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator
Number of subjects: 25
Study 11891487 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygenator
Number of subjects: 25
Study 9838911 — intervention group
Group type: EXPERIMENTAL
Intervention: FK352
Number of subjects: 0
Study 9838911 — intervention group
Group type: COMPARATOR
Intervention: mannitol
Number of subjects: 0
Study 8028406 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Health Index derived from health status measures
Number of subjects: 1862
Study 8028406 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain-specific health status scales
Number of subjects: 1862
Study 8028406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of Perceived Health Index scores
Number of subjects: 1862
Study 8028406 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MOS health status scales included in the HIV-PARSE
Number of subjects: 1862
Study 2732141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22101 (500 mg, 1000 mg, 750 mg, 1500 mg, 2000 mg)
Number of subjects: 12
Study 2732141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) with probenecid
Number of subjects: 12
Study 2732141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) without probenecid
Number of subjects: 12
Study 2732141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) via im injection
Number of subjects: 12
Study 2732141 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 22101 (continuous infusion at 280 mg/h)
Number of subjects: 12
Study 30241001 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant (100 mg/day buparlisib continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Number of subjects: 1147
Study 30241001 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (placebo continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Number of subjects: 1147
Study 30241001 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant
Number of subjects: 1147
Study 30241001 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 1147
Study 28511195 — intervention group
Group type: EXPERIMENTAL
Intervention: No motor function assessment
Number of subjects: 1359
Study 28511195 — intervention group
Group type: COMPARATOR
Intervention: Motor function assessment
Number of subjects: 1359
Study 26149444 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention package for depression, delivered by trained primary health care workers, including psychological interventions and medication based on severity and response.
Number of subjects: 0
Study 26149444 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 23806873 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Touch (slow brush stroke)
Number of subjects: 25
Study 20563663 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical‐banded gastroplasty (VBG)
Number of subjects: 100
Study 20563663 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 100
Study 20563663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (VBG and LAGB)
Number of subjects: 100
Study 17845738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group psychological intervention (PG) - three 90 minute cognitive behavioural sessions supported by an Information Booklet.
Number of subjects: 90
Study 17845738 — intervention group
Group type: EXPERIMENTAL
Intervention: Social discussion group (SDG) - received the same Information Booklet and participated in non-structured social discussion sessions.
Number of subjects: 90
Study 17845738 — intervention group
Group type: COMPARATOR
Intervention: Information Booklet group (IBG) - provided only with educational material.
Number of subjects: 90
Study 17241576 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (1 mg/kg for 12 weeks)
Number of subjects: 3500
Study 17241576 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (continuation at week 24)
Number of subjects: 3500
Study 17241576 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (36 months continuous treatment)
Number of subjects: 3500
Study 14675308 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel
Number of subjects: 0
Study 14675308 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and paclitaxel
Number of subjects: 0
Study 10953853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control with metformin
Number of subjects: 2
Study 10953853 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 2
Study 8866384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (2.0 g ampicillin + 1.0 g sulbactam every six hours)
Number of subjects: 129
Study 8866384 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (900 mg clindamycin + 1.5 mg/kg gentamicin every eight hours)
Number of subjects: 129
Study 1727614 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and short-term oral cyclophosphamide
Number of subjects: 86
Study 6373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate 0.2% ointment
Number of subjects: 485
Study 30415934 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulants (DOACs) within 3-5 days after ischaemic stroke.
Number of subjects: 9000
Study 30415934 — intervention group
Group type: EXPERIMENTAL
Intervention: Later initiation of direct oral anticoagulants (DOACs) after >7 days or >14 days post-stroke.
Number of subjects: 9000
Study 25877236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (mean BAC ≈ .08%)
Number of subjects: 62
Study 25877236 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (mean BAC ≈ .00%)
Number of subjects: 62
Study 24830741 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette
Number of subjects: 41
Study 24830741 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler
Number of subjects: 41
Study 21450377 — intervention group
Group type: EXPERIMENTAL
Intervention: Online testing as an assistant tool
Number of subjects: 146
Study 21450377 — intervention group
Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 146
Study 21450377 — intervention group
Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 146
Study 20363909 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect with accessible egalitarian response tendencies
Number of subjects: 0
Study 20363909 — intervention group
Group type: COMPARATOR
Intervention: Positive affect without accessible egalitarian response tendencies
Number of subjects: 0
Study 20363909 — intervention group
Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 0
Study 20363909 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect with counterstereotypic thoughts
Number of subjects: 0
Study 20363909 — intervention group
Group type: COMPARATOR
Intervention: Negative affect with counterstereotypic thoughts
Number of subjects: 0
Study 18574086 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 2 (IL-2)
Number of subjects: 582
Study 18574086 — intervention group
Group type: COMPARATOR
Intervention: No IL-2
Number of subjects: 582
Study 18574086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 582
Study 16096451 — intervention group
Group type: EXPERIMENTAL
Intervention: LY315920NA/S‐5920 (n = 188)
Number of subjects: 373
Study 16096451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 185)
Number of subjects: 373
Study 16096451 — intervention group
Group type: EXPERIMENTAL
Intervention: LY315920NA/S‐5920
Number of subjects: 373
Study 16096451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making with doctor
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Active role in decision-making
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about benefits of tests and treatment
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information about false test results
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information about test side-effects
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Information not provided about false results
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Information not provided about side-effects
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety about false results
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety about side-effects
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information about false results despite anxiety
Number of subjects: 652
Study 12460222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information about side-effects despite anxiety
Number of subjects: 652
Study 9607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 3‐month depot (LAD‐3M)
Number of subjects: 62
Study 7890072 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial zona dissection
Number of subjects: 32
Study 7890072 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 32
Study 2646729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (IVMP) pulse therapy (1 gm) for group 1 (one or two courses) and repeated pulses for group 2 (four to 21 months)
Number of subjects: 14
Study 2646729 — intervention group
Group type: COMPARATOR
Intervention: Repeated pulses of 1 gm of IVMP for group 2
Number of subjects: 14
Study 2646729 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3) with 21 randomized patients
Number of subjects: 14
Study 282943 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime (awake) mucociliary clearance
Number of subjects: 7
Study 282943 — intervention group
Group type: COMPARATOR
Intervention: Nighttime (asleep) mucociliary clearance
Number of subjects: 7
Study 29747706 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided online CBT‐I and sleep diary monitoring (i‐Sleep)
Number of subjects: 104
Study 29747706 — intervention group
Group type: COMPARATOR
Intervention: Sleep diary monitoring only (Control)
Number of subjects: 104
Study 28272911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (≥14 cups/week)
Number of subjects: 69
Study 28272911 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 69
Study 25733500 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 to 20 mg/ml for 5 to 7 days)
Number of subjects: 214
Study 25733500 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5-μg disk)
Number of subjects: 214
Study 25733500 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm
Number of subjects: 214
Study 25733500 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Typhi isolates
Number of subjects: 214
Study 25733500 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Paratyphi A isolates
Number of subjects: 214
Study 23835341 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α infusion
Number of subjects: 8
Study 23835341 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 8
Study 22692843 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous every 6 months)
Number of subjects: 43
Study 22692843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19399538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open approach (MO group)
Number of subjects: 30
Study 19399538 — intervention group
Group type: COMPARATOR
Intervention: Classic posterior approach (CL group)
Number of subjects: 30
Study 17318036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (10 minutes, 3 times a day, 5 days a week at 50% to 60% heart rate reserve)
Number of subjects: 24
Study 17318036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24
Study 17318036 — intervention group
Group type: COMPARATOR
Intervention: No Exercise
Number of subjects: 24
Study 15193831 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/die)
Number of subjects: 44
Study 11577621 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining worked examples that emphasized imagining procedures and concepts
Number of subjects: 0
Study 11577621 — intervention group
Group type: COMPARATOR
Intervention: Studying worked examples that emphasized understanding and remembering procedures and concepts
Number of subjects: 0
Study 9283670 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sheath
Number of subjects: 107
Study 9283670 — intervention group
Group type: COMPARATOR
Intervention: Standard sheath
Number of subjects: 107
Study 8496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-relieving caliper
Number of subjects: 0
Study 8496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral varus osteotomy
Number of subjects: 0
Study 8496357 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest and skin traction)
Number of subjects: 0
Study 2881825 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms initially as an intravenous bolus and then 250 micrograms/h via infusion)
Number of subjects: 15
Study 2881825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.15 M)
Number of subjects: 15
Study 30726962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 0
Study 30726962 — intervention group
Group type: COMPARATOR
Intervention: Continuing usual care
Number of subjects: 0
Study 29514706 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCTAug (high-dose melphalan with ixazomib)
Number of subjects: 406
Study 29514706 — intervention group
Group type: COMPARATOR
Intervention: ASCTCon (high-dose melphalan)
Number of subjects: 406
Study 29514706 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression
Number of subjects: 406
Study 29514706 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 406
Study 26897513 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐CT (Chemoradiation)
Number of subjects: 87
Study 26897513 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐HT (Radiotherapy combined with hyperthermia)
Number of subjects: 87
Study 25240761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod (TASQ)
Number of subjects: 201
Study 25240761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 22377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive ER formulation with immediate release component (IR/ER)
Number of subjects: 14
Study 22377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive ER formulation without immediate release component (ER)
Number of subjects: 14
Study 22377973 — intervention group
Group type: COMPARATOR
Intervention: Conventional ER tablet (C-ER)
Number of subjects: 14
Study 22377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger tapping test
Number of subjects: 14
Study 20637388 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal CO2 measured by a microstream capnometer
Number of subjects: 43
Study 17585027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg) capsules daily
Number of subjects: 118
Study 17585027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16129717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity program)
Number of subjects: 16
Study 16129717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 15253389 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse cases (PB leprosy)
Number of subjects: 256
Study 15253389 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse cases (MB leprosy)
Number of subjects: 256
Study 15253389 — intervention group
Group type: EXPERIMENTAL
Intervention: History of contact with an active leprosy patient and irregular treatment
Number of subjects: 256
Study 15253389 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial BI of 3+
Number of subjects: 256
Study 15253389 — intervention group
Group type: COMPARATOR
Intervention: Control cases (Not relapse)
Number of subjects: 256
Study 10955437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol-releasing vaginal ring for 24 weeks
Number of subjects: 251
Study 10955437 — intervention group
Group type: COMPARATOR
Intervention: Oestriol pessaries 0.5 mg every second day for 24 weeks
Number of subjects: 251
Study 10955437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol-releasing vaginal ring
Number of subjects: 251
Study 10955437 — intervention group
Group type: COMPARATOR
Intervention: Oestriol pessaries
Number of subjects: 251
Study 8837670 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfume provocation
Number of subjects: 9
Study 8837670 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon filter mask during perfume provocation
Number of subjects: 9
Study 8837670 — intervention group
Group type: COMPARATOR
Intervention: Placebo provocation
Number of subjects: 9
Study 1408546 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 53
Study 1408546 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced formula
Number of subjects: 53
Study 1408546 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (lactose)
Number of subjects: 53
Study 3973310 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (71 challenges with doses ranging from 5 to 100 gm)
Number of subjects: 25
Study 3973310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 placebos administered)
Number of subjects: 25
Study 3973310 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey (10-12 months)
Number of subjects: 25
Study 3973310 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive food challenges
Number of subjects: 25
Study 3543241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (FAC: fluorouracil, doxorubicin, cyclophosphamide) in a protected environment with prophylactic antibiotics
Number of subjects: 33
Study 3543241 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital room treatment
Number of subjects: 33
Study 31091611 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV+sIPV+bOPV
Number of subjects: 151
Study 31091611 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV+wIPV+bOPV
Number of subjects: 151
Study 31091611 — intervention group
Group type: EXPERIMENTAL
Intervention: wIPV+sIPV+bOPV
Number of subjects: 151
Study 31091611 — intervention group
Group type: EXPERIMENTAL
Intervention: wIPV+wIPV+bOPV
Number of subjects: 151
Study 28486879 — intervention group
Group type: EXPERIMENTAL
Intervention: Single novel imaginal intervention session
Number of subjects: 98
Study 28486879 — intervention group
Group type: COMPARATOR
Intervention: 15‐min meditation (control group)
Number of subjects: 98
Study 26519708 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 200
Study 26519708 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 200
Study 24555234 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 0
Study 21470288 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)FDG‐PET/CT scan
Number of subjects: 88
Study 18337077 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulmonary rehabilitation programme (18 weeks)
Number of subjects: 239
Study 18337077 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 239
Study 18337077 — intervention group
Group type: EXPERIMENTAL
Intervention: More previous hospital admissions
Number of subjects: 239
Study 18337077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Medical Research Council (MRC) dyspnoea score
Number of subjects: 239
Study 18337077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enduring a long journey to the PR centre
Number of subjects: 239
Study 18337077 — intervention group
Group type: COMPARATOR
Intervention: Short pulmonary rehabilitation programme (6 weeks)
Number of subjects: 239
Study 16502116 — intervention group
Group type: EXPERIMENTAL
Intervention: risedronate
Number of subjects: 27
Study 16502116 — intervention group
Group type: COMPARATOR
Intervention: antithyroid drug only
Number of subjects: 27
Study 12772816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast potassium 0.1%
Number of subjects: 80
Study 12772816 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium 2%
Number of subjects: 80
Study 10703904 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna 7cH and X‐ray 15cH
Number of subjects: 66
Study 10703904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9258850 — intervention group
Group type: EXPERIMENTAL
Intervention: All-out effort against an applied resistance of 7.5% of body weight (test 1)
Number of subjects: 7
Study 9258850 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant pace of 55% of the peak pedal rate of test 1 against a resistance of 10.9 +/- 0.4% of body weight (test 2)
Number of subjects: 7
Study 9258850 — intervention group
Group type: EXPERIMENTAL
Intervention: All-out effort against the greater resistance (test 3)
Number of subjects: 7
Study 8479036 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery-preserved group
Number of subjects: 34